Roberto Buzzoni - Concepedia

Author

Roberto Buzzoni

Fondazione IRCCS Istituto Nazionale dei Tumori

Also Known As

Alessandro Bertolini, Buzzoni, Roberto, M Di Bartolomeo, R BUZZONI, R Buzzoni, R. Buzzoni, Roberto Buzzoni, S. Monjardini

218

Publications

6.3K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori European Institute of Oncology Novartis (Switzerland)University of Milan The University of Texas MD Anderson Cancer Center

About

Roberto Buzzoni is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	45	3K
2	Health Sciences	7	7	260
3	Endocrinology	7	7	242
4	Cell Biology	1	1	20
5	Diabetes	1	1	87

Roberto Buzzoni

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study James C. Yao, Nicola Fazio, Simron Singh, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2015	1.2K
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group Maria Di Bartolomeo, Emilio Bajetta, Roberto Buzzoni, Cancer	1996	296
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories Massimo Milione, Patrick Maisonneuve, Francesca Spada, Neuroendocrinology	2016	236
Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women Emilio Bajetta, Giuseppe Procopio, Luigi Celio, Journal of Clinical Oncology	2005	208
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors Vincenzo Mazzaferro, Carlo Sposito, Jorgelina Coppa, American Journal of Transplantation	2016	207
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. Roberto Buzzoni, Gianni Bonadonna, Pinuccia Valagussa, Journal of Clinical Oncology Surgical OncologyHigh-risk Breast CancerBreast OncologyAdjuvant ChemotherapyPharmacotherapy	1991	163
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. Emilio Bajetta, Angelo Di Leo, Laura Biganzoli, Journal of Clinical Oncology	1996	140
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group Emilio Bajetta, Roberto Buzzoni, Luigi Mariani, Annals of Oncology Surgical OncologyItalian TrialsGastrointestinal OncologyMedicineAdjuvant Chemotherapy	2002	137
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma Emilio Bajetta, Maria Di Bartolomeo, Luigi Mariani, Cancer	2004	135
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group Emilio Bajetta, Nicoletta Zilembo, Maria Di Bartolomeo, Cancer	1993	128

Page 1